8-K: Oncolytics Biotech to Present Strong Pelareorep Data at AACR

Oncolytics Biotech announced two abstracts on pelareorep's immune-priming capabilities in pancreatic and breast cancer were accepted for presentation at the AACR Annual Meeting 2026.

Summary

• Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure (TLS) formation, supporting its role as an immune-priming agent.
• Translational data suggest pelareorep has the potential to boost response to immunotherapy and targeted therapy in RAS-driven tumors, which are highly prevalent in pancreatic and colorectal cancers.
• Biomarker data from Cohort 1 of the Phase 1/2 GOBLET trial in metastatic pancreatic ductal adenocarcinoma (mPDAC) showed pelareorep combined with atezolizumab and chemotherapy can shift tumors toward a more immune-active state.
• Patients in the GOBLET study demonstrating immune activation signatures experienced longer median progression-free survival (7.5 months) compared to those without similar immune responses (5.6 months).
• The GOBLET combination therapy achieved a 62% objective response rate in first-line mPDAC patients, which is more than double the response rates historically observed with chemotherapy alone.
• First-of-its-kind data from the AWARE-1 study in early breast cancer demonstrated pelareorep's ability to drive anti-tumor immune responses, including TLS formation, potentially converting immunologically 'cold' tumors into 'hot' tumors.
• Pelareorep has also been shown to stimulate RAS-specific T-cell clones in gastrointestinal cancers, which may enhance its ability to target RAS-mutated tumor cells.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive announcement due to strong clinical data showing significant improvements in response rates and progression-free survival in difficult-to-treat cancers, coupled with a clear mechanistic understanding of pelareorep's immune-priming effects.

Positives

• Pelareorep demonstrates strong immune-priming capabilities, reshaping the tumor microenvironment and driving coordinated immune activation and tertiary lymphoid structure formation.
• Translational data suggest pelareorep can boost response to immunotherapy and targeted therapy in RAS-driven tumors, addressing a significant unmet need in prevalent deadly cancers.
• The GOBLET study reported a 62% objective response rate in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients, more than double historical chemotherapy alone rates.
• Patients with an immune activation signature in the GOBLET study experienced longer median progression-free survival (7.5 months vs. 5.6 months).
• AWARE-1 data indicates pelareorep can convert immunologically 'cold' tumors into 'hot' tumors, making them more susceptible to immunotherapy, including for patients who have failed checkpoint inhibitors.
• Pelareorep stimulates RAS-specific T-cell clones in gastrointestinal cancers, enhancing its ability to target RAS-mutated tumor cells.
• The company has received Fast Track designation from the FDA for pelareorep in colorectal and pancreatic cancer.

Risks

• Regulatory outcomes may not be favorable or timely.
• Clinical trial execution may face challenges or delays.
• The company's financial resources may be insufficient for continued development.
• Access to capital markets may be limited or unfavorable.
• Market dynamics could negatively impact product adoption or pricing.

Future Outlook

Oncolytics believes pelareorep will enhance immunotherapy activity and potentially help patients who did not respond initially, especially as they advance registrational programs in gastrointestinal cancers. The company is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. More data on RAS-specific T-cell clones is expected to be presented at an upcoming scientific meeting.

Management Comments

• "These new translational findings strengthen our understanding of pelareorep as a systemic immunepriming agent that reshapes the tumor microenvironment." Jared Kelly, Chief Executive Officer of Oncolytics.
• "The coordinated immune activation and tertiary lymphoid structure formation we are observing support pelareorep as a foundational backbone for combination therapy across multiple tumor types, including RAS-driven cancers." Jared Kelly, Chief Executive Officer of Oncolytics.
• "As we advance registrational programs in gastrointestinal cancers, we believe pelareorep will enhance immunotherapy activity and potentially help patients who did not respond initially." Jared Kelly, Chief Executive Officer of Oncolytics.

Industry Context

StockSavvy.ai notes that the focus on immune-priming and converting 'cold' tumors to 'hot' aligns with a major trend in oncology to overcome resistance to existing immunotherapies, particularly checkpoint inhibitors. The emphasis on RAS-driven cancers addresses a significant unmet need, as these mutations are highly prevalent in aggressive cancers like pancreatic and colorectal cancer, which are notoriously difficult to treat. The reported doubling of response rates in mPDAC with pelareorep combination therapy, compared to historical chemotherapy, suggests a potentially significant advancement in a challenging disease area.

Comparison to Industry Standards

• The 62% objective response rate in first-line mPDAC patients with pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel is more than double the response rates historically observed with chemotherapy alone.
• Pancreatic cancer has approximately 510,000 new cases reported globally each year, highlighting the significant unmet clinical need addressed by these findings.
• RAS mutations are especially prevalent in deadly cancers, including roughly 95% of pancreatic cancers and 45% of colorectal cancers, indicating pelareorep's potential impact on a large patient population.
• The ability to form Tertiary Lymphoid Structures (TLS) is linked to improved responses to immunotherapy in published studies, suggesting pelareorep's mechanism aligns with known positive indicators for treatment efficacy.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical data, potential for increased market value, and strategic partnerships.
• Patients: Potential for improved treatment outcomes, especially in difficult-to-treat pancreatic and breast cancers, and for those who have failed prior immunotherapies.
• Medical Community: New insights into immune-priming mechanisms and potential combination therapies for challenging tumor types.

Next Steps

• Presentation of two abstracts at the AACR Annual Meeting 2026 (April 17-22, 2026).
• Advancing registrational programs in gastrointestinal cancers.
• Presentation of more data on RAS-specific T-cell clones at an upcoming scientific meeting.
• Actively pursuing strategic partnerships to accelerate development and maximize commercial impact.

Key Dates

Recommendation

The filing presents compelling positive clinical data from two studies (GOBLET and AWARE-1) demonstrating pelareorep's significant potential to improve treatment outcomes in highly aggressive and difficult-to-treat cancers like metastatic pancreatic ductal adenocarcinoma and breast cancer. The reported objective response rate in mPDAC, more than double historical chemotherapy rates, is particularly noteworthy. The mechanistic data supporting immune activation and tertiary lymphoid structure formation provides a strong scientific rationale. These results, combined with the FDA's Fast Track designation, suggest a high probability of future clinical and commercial success, making the stock a strong buy for investors seeking exposure to innovative oncology therapeutics.

Keywords

Oncolytics Biotech, ONCY, pelareorep, immunotherapy, cancer, AACR, pancreatic cancer, breast cancer, GOBLET study, AWARE-1 study, RAS-driven tumors, immune-priming, checkpoint inhibitors, targeted therapy, chemotherapy, oncology, clinical-stage, biotechnology, metastatic pancreatic ductal adenocarcinoma, mPDAC, tertiary lymphoid structures, TLS, atezolizumab, gemcitabine, nab-paclitaxel, Fast Track designation